Logo-aim
Arch Iran Med. 2021;24(10): 779-782. doi: 10.34172/aim.2021.115

Review Article

Biosimilars in Treatment of Multiple Sclerosis in Iran

Abdorreza Naser Moghadasi 1 * ORCID

Cited by CrossRef: 2


1- Greenberg B, Giovannoni G. A place for biosimilars in the changing multiple sclerosis treatment landscape. Multiple Sclerosis and Related Disorders. 2023;77:104841 [Crossref]
2- Brownlee W, Wolf C, Hartung H, Dingermann T, Anshasi N, Clark R, Trojano M, Selmaj K, Uitdehaag B, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen J. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Mult Scler. 2022;28(14):2177 [Crossref]


SCImago Journal & Country Rank

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.